HRS4R
Vull donar
Firma
SONIA DEL BARCO-BERRON
Posició
Investigadors/es Col·laboradors/es
Investigadors/es Col·laboradors/es

Publicacions

0

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).

CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24, 703-711 dx.doi.org/10.1007/s12094-022-02803-0
0

In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma

SCIENTIFIC REPORTS, 2022, 12, 14439-14439 dx.doi.org/10.1038/s41598-022-18608-8
0

Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer

CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24, 1033-1046 dx.doi.org/10.1007/s12094-021-02766-8

Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí O, Martinez Garcia M, Mallo M, Gut M, Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T, Oleaga L, Gil-Gil MJ, de Quintana-Schmidt C, Valduvieco I, Martinez-Cardus A, Bellosillo B, Muñoz-Mármol AM, Esteve A, Domenech M, Camins A, Craven-Bartle J, Villa S, Marruecos J, Domenech S, de la Iglesia N, Balana C

RNA-Sequencing and immunohistochemistry reveal ZFN7 as a stronger marker of survival than molecular subtypes in G-CIMP-negative glioblastoma.

CLINICAL CANCER RESEARCH, 2021, 27, 645-655 dx.doi.org/10.1158/1078-0432.CCR-20-2141

Luque R, Benavides M, Del Barco S, Egaña L, García-Gómez J, Martínez-García M, Pérez-Segura P, Pineda E, Sepúlveda JM, Vieito M

SEOM clinical guideline for management of adult medulloblastoma (2020).

CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23, 940-947 dx.doi.org/10.1007/s12094-021-02581-1

Carrato C, Alameda F, Esteve-Codina A, Pineda E, Arpí O, Martinez Garcia M, Mallo M, Gut M, Lopez-Martos R, Del Barco S, Ribalta T, Capellades J, Puig J, Gallego O, Mesia C, Muñoz-Mármol AM, Archilla I, Arumí M, Blanc JM, Bellosillo B, Menéndez S, Esteve A, Bague S, Hernandez A, Craven-Bartle J, Fuentes R, Vidal N, Aldecoa I, de la Iglesia N, Balana C

Glioblastoma TCGA mesenchymal and IGS 23 tumors are identifiable by immunohistochemistry and have an immune-phenotype indicating potential benefit from immunotherapy.

CLINICAL CANCER RESEARCH, 2020, 26, 6600-6609 dx.doi.org/10.1158/1078-0432.CCR-20-2171

Balana C, Vaz MA, Sepúlveda JM, Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las Peñas R, Fuster J, Gironés R, Navarro LM, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-García M, Berrocal A, Gallego O, Luque R, Perez-Martín FJ, Esteve A, Munne N, Domenech M, Villa S, Sanz C, Carrato C

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01).

Neuro-Oncology, 2020, 22, 1851-1861 dx.doi.org/10.1093/neuonc/noaa107

Vila MM, Barco Berron SD, Gil-Gil M, Ochoa-Arnedo C, Vázquez RV

Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer.

Breast, 2020, 53, 44-50 dx.doi.org/10.1016/j.breast.2020.06.007

Puig J, Biarnés C, Daunis-I-Estadella P, Blasco G, Gimeno A, Essig M, Balaña C, Alberich-Bayarri A, Jimenez-Pastor A, Camacho E, Thio-Henestrosa S, Capellades J, Sanchez-Gonzalez J, Navas-Martí M, Domenech-Ximenos B, Del Barco S, Puigdemont M, Leiva-Salinas C, Wintermark M, Nael K, Jain R, Pedraza S

Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma.

Cancers, 2019, 11 dx.doi.org/10.3390/cancers11010084

Losada B, Guerra JA, Malón D, Jara C, Rodriguez L, Del Barco S

Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21, 855-863 dx.doi.org/10.1007/s12094-018-1999-9

Formulari de contacte

Coneix l’IDIBGI!

menu